The US-based biotech company Moderna said Monday that early analysis from a phase 3 COVID-19 vaccine trails shows it is 94.5 percent effective against infection.
Moderna's announcement comes one week after drugmaker Pfizer and its German partner BioNTech said an early look at data from its potential COVID-19 vaccine shows it to be more than 90% effective.
The one benefit that Moderna announced with it's vaccine is that it does not require "ultra-cold storage" but rather a simple refridgeration model to keep it viable, making it an easier option to transport and distribute worldwide.
“I think this is a really strong step forward to where we want to be about getting control of this outbreak,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the TODAY show after Moderna’s announcement, calling the company’s vaccine data “quite impressive.”
COVID-19 vaccines are being carefully evaluated in clinical trials and will be authorized or approved only if they make it substantially less likely you’ll get COVID-19, said a statement from the CDC. "Based on what we know about vaccines for other diseases, experts believe that getting a COVID-19 vaccine may help keep you from getting seriously ill even if you do get COVID-19."